XT
ALGS icon

XTX Topco’s Aligos Therapeutics ALGS Stock Holding History

XTX Topco’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$105K Sell
14,196
-8,857
-38% -$67.2K ﹤0.01% 3086
2025
Q4 		$215K Buy
+23,053
New +$217K 0.01% 2346
2025
Q3 		– Sell
-13,849
Closed -$99.9K – 2514
2025
Q2 		$99.9K Buy
+13,849
New +$82.9K ﹤0.01% 1886
2024
Q3 		– Sell
-1,426
Closed -$12.5K – 2043
2024
Q2 		$12.5K Sell
1,426
-369
-21% -$6.49K ﹤0.01% 1670
2024
Q1 		$44K Buy
1,795
+765
+74% +$15.2K 0.01% 1488
2023
Q4 		$17.1K Buy
+1,030
New +$17.7K ﹤0.01% 1380
2022
Q2 		– Sell
-1,757
Closed -$94K – 825
2022
Q1 		$94K Buy
+1,757
New +$141K 0.04% 525

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

XTX Topco's ALGS Position: Q1 2026 in Review

XTX Topco reduced its Aligos Therapeutics (ALGS) stake by 38% in Q1 2026, selling an estimated $67.2K and leaving 14,196 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #3086.

XTX Topco first reported a position in ALGS in Q1 2022 and has held it in 7 quarters since. The position peaked at $215K in Q4 2025. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

  • XTX Topco held 14,196 shares of Aligos Therapeutics worth $105K as of Q1 2026.
  • XTX Topco sold 8,857 Aligos Therapeutics shares in Q1 2026, an estimated $67.2K.
  • Aligos Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #3086 holding.
  • XTX Topco first reported a position in Aligos Therapeutics in Q1 2022 and has held it in 7 quarters since.
  • XTX Topco's Aligos Therapeutics position peaked at $215K in Q4 2025.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.